reports
Adverum Biotechnologies Reports First Quarter 2024 Financial Results a...
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial resul...
Clearside Biomedical Announces First Quarter 2024 Financial Results an...
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update - Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarte...
Larimar Therapeutics Reports First Quarter 2024 Operating and Financia...
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was generally well-tolerated with dose-dependent increases in tissue frataxin levels, reinforcing therapeutic potentialBiologics License Application (“BLA”) submission targeted for 2H 2025; discussions initiated with Food and Drug Administration (“FDA”) on potential to pursue accelerated approval pathwaySuc...
- Jonathan Moreland
RM REGIONAL MANAGEMENT CORP
PENN PENN NATIONAL GAMING INC.
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
EFR ENERGY FUELS
MAC MACERICH COMPANY
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
VSTS_w THE BANCORP
EYPT INC.
VESTIS CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Re...
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE® Successfully Commenced the U.S. Launch of AGAMREE® on March 13, 2024 Reported AGAMREE® Q1 2024 Net Product Revenues of $1.2 Million for the First Two Weeks of Commercial Availability Early AGAMREE® Launch I...
Clearside Biomedical to Participate in Fireside Chat at the Citizens J...
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m. ET in...
PennantPark Investment Corporation Announces 14.3% Increase of Its Mon...
PennantPark Investment Corporation Announces 14.3% Increase of Its Monthly Distribution to $0.08 per share and Financial Results for the Quarter Ended March 31, 2024 MIAMI, May 08, 2024 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) announced today its financial results for the second quarter ended March 31, 2024. HIGHLIGHTS Quarter ended March 31, 2024 (unaudited)($ in millions, except per share amounts) Assets and Liabilities: Investment portfolio(1)$1,238.2 Net assets$501.5 GAAP net asset value per share$7.69 Quarterly increase in...
Sana Biotechnology Reports First Quarter 2024 Financial Results and Bu...
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Ongoing ARDENT trial for SC291 continues in B-cell malignancies; expect to report additional data in 2024 Enrolling patients in the ongoing GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in the ongoing VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to rep...
EMCORE Reports Fiscal 2024 Second Quarter Results
EMCORE Reports Fiscal 2024 Second Quarter Results BUDD LAKE, NJ, May 08, 2024 (GLOBE NEWSWIRE) -- EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, today announced results for the fiscal 2024 second quarter (2Q24) ended March 31, 2024. Management will host a conference call to discuss 2Q24 financial and business results on May 8, 2024 at 5:00 p.m. Eastern Time (ET). “Lower-than-expected revenue in the March quarter was primarily due to product shipment delays and declining revenue from our B...
America’s Car-Mart, Inc. to Announce the Fourth Quarter and Full Fisca...
America’s Car-Mart, Inc. to Announce the Fourth Quarter and Full Fiscal Year 2024 Results Conference Call Moved Earlier to 9am ET ROGERS, Ark. , May 08, 2024 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fourth quarter and full fiscal year financial results on Tuesday, June 18, 2024, before the market opens and senior management will host a conference call at 9:00 a.m ET to discuss the results. Participants may access the conference call via webcast using this link: . To participate via telephone, please register in advance using this . Upo...
- Jonathan Chaplin
Hillenbrand Inc: 4 directors
Four Directors at Hillenbrand Inc bought/maiden bought 6,237 shares at between 42.105USD and 42.690USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Herbalife Ltd: 1 director
A director at Herbalife Ltd bought 30,000 shares at 9.650USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Hawthorn Bancshares Inc: 1 director
A director at Hawthorn Bancshares Inc bought 15,000 shares at 19.626USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Jonathan Moreland
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
LTRX LANTRONIX INC.
HXL HEXCEL CORPORATION
HOO HERBALIFE NUTRITION LTD.
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
EAF GRAFTECH INTERNATIONAL
GH GUARDANT HEALTH
DNA GINKGO BIOWORKS HOLDINGS
TBBK INC.
RXO_w THE BANCORP
VSTS_w INC.
CFFI RXO INC
RENT VESTIS CORPORATION
C&F FINANCIAL CORPORATION
RENT THE RUNWAY INC
Sana Biotechnology to Present at May and June 2024 Investor Conference...
Sana Biotechnology to Present at May and June 2024 Investor Conferences SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update. Sana will present at the Citizens JMP Securities Life Sciences Conference at 11:30 a.m. ET on Monday, May 13, 2024.Sana will present at the BofA Securities 2024 Healthcare Conference at 3:...
America’s Car-Mart, Inc. Schedules Release of Fourth Quarter Fiscal Ye...
America’s Car-Mart, Inc. Schedules Release of Fourth Quarter Fiscal Year 2024 Results and Conference Call ROGERS, Ark., May 06, 2024 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2024 fourth quarter financial results on Tuesday, June 18, 2024, before the market opens, and senior management will host a conference call at 11:00 a.m. ET to discuss the results. Participants may access the conference call via webcast using this link: . To participate via telephone, please register in advance using this . Upon registration, all telephone par...
- Jonathan Chaplin
Autumn for Broadband 1Q24
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Industry net adds were substantially weaker in 1Q24 with all technologies seeing slower growth (except DSL which was flat). Cable was impacted the most.
- Jonathan Moreland
RF REGIONS FINANCIAL CORPORATION
NEOG NEOGEN CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
EGBN EAGLE BANCORP INC.
DLTR DOLLAR TREE INC.
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
SWKS SKYWORKS SOLUTIONS INC.
HTLD HEARTLAND EXPRESS INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
CET CENTRAL SECURITIES CORP.
LIND LINDBLAD EXPEDITIONS HOLDINGS
WDFC WD-40 COMPANY
FEIM FREQUENCY ELECTRONICS INC.
AINC ASHFORD
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
ATOM ATOMERA
LOVE LOVESAC
FVCB FVCBANKCORP
INMB INMUNE BIO
MCFT INC.
CAPR MASTERCRAFT BOAT HOLDINGS
RYES CAPRICOR THERAPEUTICS
HQL PATRIOT MINEFINDERS INC.
SOWG TEKLA LIFE SCIENCES INVESTORS
CPZ SOW GOOD INC.
AUID CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
JBHT IPSIDY INC.
TBBK J.B. HUNT TRANSPORT SERVICES
MPA INC.
FTHY THE BANCORP
AIKI INC.
BHVN BLACKROCK MUNIYIELD PENNSYLVANIA FD
BUKS FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
ACRV AIKIDO PHARMA INC.
ZURA BIOHAVEN LTD
ABEO BUTLER NATIONAL CORP
STCN ACRIVON THERAPEUTICS INC
KRRO ZURA BIO LTD
LSXMA ABEONA THERAPEUTICS INC.
EP STEEL CONNECT INC
INTZ KORRO BIO INC
LGVN LIBERTY SIRIUSXM GROUP
OCX EMPIRE PETROLEUM CORP
EYPT INTRUSION INC
IZEA LONGEVERON INC
CFFI ONCOCYTE CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
IZEA WORLDWIDE INC
C&F FINANCIAL CORPORATION
Adverum Biotechnologies to Participate in Upcoming May Investor Confer...
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright 2nd Annual BioCon...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.